View Invitation - Abramson Cancer Center

Penn Medicine’s Abramson Cancer Center
and the Leukemia & Lymphoma Society P R E S E NT
UPDATE IN
HEMATOLOGIC CANCERS
With Proceedings from International Medical Meetings
REGISTER ONLINE AT PENNCANCER.ORG/CME/BLOOD
CME/CE-Certified Course
FR IDAY, JAN U ARY 3 0 , 2 0 1 5
8:00 A.M. – 4:00 P.M.
Hub Cira Center
2929 Arch Street | Mezzanine Level
Philadelphia, PA 19104
For directions and parking go to
www.thehub.com/maps-cira.php
Parking fees are not covered by this course.
UPDATE IN
HEMATOLOGIC
CANCERS
With Proceedings from
International Medical Meetings
FRIDAY, JANUARY 30
2015
8:00 A.M. – 4:00 P.M.
HUB CIRA CENTER
2929 Arch Street
Mezzanine Level
Philadelphia, PA 19104
DIRECTIONS AND PARKING
The Hub Cira Center is located at
2929 Arch Street, Mezzanine Level,
Philadelphia, PA 19104. Directions and
parking information can be found at
www.thehub.com/maps-cira.php. Parking
fees are not covered by this course.
OVERVIEW
This course is designed to be a comprehensive update
of new treatment approaches recently incorporated into
patient management, including the different types of
hematologic malignancies and how clinicians should evolve
therapeutic approaches based on factors, such as tumor
classification and response. Penn faculty will discuss recent
technological advances in blood cancers that will provide a
perspective on clinical data presented at major international
medical meetings.
OBJECTIVES
Upon completion of this course, participants should be
able to:
• Discuss clinical features, including differential
diagnoses of the various hematologic malignancies
• Describe recent advances in treatment for the
various hematologic malignancies
• Summarize the major patient management issues
associated with hematologic malignancies
• Identify and manage long-term and late-effects of
treatment for hematologic cancers, including bone
marrow transplant
• Define the state-of-the-art for genomic analyses for
hematologic malignancies
• Apply new strategies for incorporating therapies
that target metabolism in blood cancers
WHO SHOULD ATTEND
The target audience is hematologists, medical and
radiation oncologists, primary care physicians,
pathologists, hematology/oncology fellows, oncology
nurses, oncology social workers, and other healthcare
professionals involved in the treatment of patients
with blood cancer.
Please note that most of the conference materials will be
available online. Please bring your electronic device to
view presentations in real time.
AGENDA
8:00 am
8:30 am
Registration and Continental Breakfast
Welcome and Introduction
Chi V. Dang, MD, PhD
Edward A. Stadtmauer, MD
M OR NI NG S ESS I O N
8:40 am
Hematologic Malignancies Translational Center of Excellence
Edward A. Stadtmauer, MD
Controversies and Updates in Multiple Myeloma
Moderator: Edward A. Stadtmauer, MD
9:00 am Update on MGUS, Smoldering Myeloma and Amyloidosis
Brendan M. Weiss, MD
9:20 am
Experimental Therapies for Relapsed Myeloma
Dan T. Vogl, MD
9:40 am
Latest Transplant Approaches for Myeloma
Adam D. Cohen, MD
10:00 am
Panel Discussion with Question and Answer Session
10:15 am
BREAK
Moderator: Edward A. Stadtmauer, MD
Panel: Adam D. Cohen, MD
Dan T. Vogl, MD
Brendan M. Weiss, MD
Transplant and Cellular Therapies
Moderator: David L. Porter, MD
10:30 am
Graft versus Host Disease
10:50 am
ellular Therapy for Blood Cancers
C
David L. Porter, MD
11:10 am
S urvivorship after Hematopoietic Cell Transplantation
Alison W. Loren, MD, MS
11:30 am
anel Discussion with Question and Answer Session
P
Moderator: David L. Porter, MD
Panel: Alison W. Loren, MD, MS
Ran Reshef, MD, MSc
11:45 am
LUNCH
Ran Reshef, MD, MSc
AF T E R NO O N S E SS I O N
Updates on Treatment Strategies in Leukemia
Moderator: Selina M. Luger, MD
12:45 pm
Update in Treatment Strategies for Leukemia
1:05 pm
Latest Treatments for Acute Lymphocytic Leukemia
1:25 pm
1:45 pm
Alexander E. Perl, MD
Noelle V. Frey MD, MSCE
Latest Update in Myeloproliferative Disease
Elizabeth O. Hexner, MD
Emerging Treatment Options for Myelodysplastic Syndromes
James K. Mangan, MD, PhD
2:05 pm
Panel Discussion with Question and Answer Session
Moderator: Selina M. Luger, MD
Panel: Alexander E. Perl, MD
Noelle V. Frey, MD, MSCE
Elizabeth O. Hexner, MD
James K. Mangan, MD, PhD
New Therapies and Current Management of Lymphomas
Moderator: Stephen J. Schuster, MD
2:25 pm
New Therapies and Current Management of Lymphomas
Stephen J. Schuster, MD
2:45 pm
Therapeutic Advances in Hodgkin Lymphoma
Jakub Svoboda, MD
3:05 pm
Aggressive Lymphomas
Sunita D. Nasta, MD, FACP
3:25 pm
Chronic Lymphocytic Leukemia
Anthony R. Mato, MD, MSCE
3:45 pm
Panel Discussion with Question and Answer Session
Moderator: Stephen J. Schuster, MD
Panel: Jakub Svoboda, MD
Anthony R. Mato, MD, MSCE
Sunita D. Nasta, MD, FACP
4:00 pm
Evaluation and Adjourn
SPEAKERS
COURSE DIRECTOR
Edward A. Stadtmauer, MD
Professor, Medicine
Chief, Hematologic Malignancies Section
Division of Hematology Oncology
Co-Leader, Hematologic Malignancies
Research Program
COURSE CO-DIRECTORS
Selina M. Luger, MD
Professor, Medicine
Division of Hematology Oncology
Director, Leukemia Program
David L. Porter, MD
Jodi Fisher Horowitz Professor of Leukemia
Care Excellence
Division of Hematology Oncology
Director, Blood and Marrow Transplantation
Stephen J. Schuster, MD
Robert and Margarita Louis-Dreyfus
Associate Professor of Chronic Lymphocytic
Leukemia and Lymphoma
Division of Hematology Oncology
Director, Lymphoma Program and Lymphoma
Translational Research
PENN MEDICINE FACULTY
Adam D. Cohen, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Chi V. Dang, MD, PhD
John H. Glick, MD
Abramson Cancer Center Director’s
Professor of Medicine
Director, Abramson Cancer Center
Noelle V. Frey, MD, MSCE
Assistant Professor, Medicine
Division of Hematology Oncology
Elizabeth O. Hexner, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Alison W. Loren, MD, MS
Assistant Professor of Medicine
Division of Hematology Oncology
James K. Mangan, MD, PhD
Assistant Professor, Medicine
Division of Hematology Oncology
Anthony R. Mato, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Director, Chronic Lymphocytic Leukemia Program
Sunita D. Nasta, MD, FACP
Assistant Professor, Medicine
Division of Hematology Oncology
Alexander E. Perl, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Ran Reshef, MD, MSc
Assistant Professor, Medicine
Division of Hematology Oncology
Jakub Svoboda, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Dan T. Vogl, MD
Assistant Professor, Medicine
Division of Hematology Oncology
Brendan M. Weiss, MD
Assistant Professor, Medicine
Division of Hematology Oncology
REGISTRATION
The registration fee for practicing physician is
$100.00. For non-Penn resident, fellow, nurse, and
other healthcare professional, the fee is $50.00.
For faculty, staff, resident, fellow and/or student of
the University of Pennsylvania, the fee is $50.00.
We accept Visa, Discover, MasterCard, and
American Express. Registration includes breakfast,
lunch, breaks and online course syllabus.
R E G I S TE R O N L I N E AT
PennCancer.org/CME/Blood
ACCREDITATION AND
DESIGNATION OF CREDIT
HOSTING DEPARTMENT
Update in Hematologic Cancers: with Proceedings
from International Medical Meetings is hosted by the
Abramson Cancer Center of the University of Pennsylvania
and The Leukemia & Lymphoma Society.
ACCREDITATION
The Perelman School of Medicine at the University of
Pennsylvania is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
DESIGNATION OF CREDIT
PHYSICIANS: The Perelman School of Medicine at the
University of Pennsylvania designates this live activity for a
maximum of 6 AMA PRA Category 1 Credit™. Physicians
should claim only the credit commensurate with the extent
of their participation in the activity.
AAPA: AAPA accepts certificates of participation for
educational activities certified for Category 1 credit from
AOACCME, prescribed credit from AAFP, and AMA PRA
Category 1 Credit™.
NURSES AND SOCIAL WORKERS: Approval for nurses
has been obtained by the National Office of The Leukemia
& Lymphoma Society under provider number CEP 5832
to award 6.5 continuing education contact hour(s) through
the California Board of Registered Nursing. The Leukemia
& Lymphoma Society (LLS), provider number 1105, is
approved as a provider for social work continuing education
by the Association of Social Work Boards (ASWB)
www.aswb.org Approved Continuing Education Program
(ACE). Approval Period: 12/2014 to 12/2017. LLS maintains
responsibility for the program. Social workers should
contact their regulatory board to determine course approval.
Social workers will receive 6.5 CE clinical clock hour(s).
DISCLOSURES
The Perelman School of Medicine at the University
of Pennsylvania, Office of Continuing Medical
Education, adheres to the ACCME Standards for
Commercial Support. Faculty disclosures information
will be made available in the conference materials
and syllabi. Faculty members are also expected to
disclose to participants any discussion of off-label and/
or investigational use of pharmaceutical products or
devices within their presentations.
CANCELLATION POLICY
In order to process refunds for course withdrawals,
cancellations must be received in writing by January
16, 2015 and are subject to a service charge
equivalent to 10% of the registration fee. No refunds
will be issued thereafter.
The University reserves the right to cancel or postpone
this course due to unforeseen circumstances. In the
event of a cancellation or postponement, the University
will refund registration fees but is not responsible for
related costs or expenses to participants, including
cancellation fees assessed by hotels, airlines, and
travel agencies.
SERVICES FOR THE DISABLED
If special arrangements are required for an individual
with a disability to attend this course, please contact
Barbara Lopez at Barbara.Lopez@uphs.upenn.edu
or 215-614-1954 no later than January 16, 2015.
NONDISCRIMINATION STATEMENT
The University of Pennsylvania values diversity and
seeks talented students, faculty, and staff from diverse
backgrounds. The University of Pennsylvania does
not discriminate on the basis of race, sex, sexual
orientation, gender identity, religion, color, national or
ethnic origin, age, disability, or status as a Vietnam
Era Veteran or disabled veteran in the administration
of educational policies, programs or activities;
admission policies; scholarship and loan awards;
athletic, or other University administered programs or
employment. Questions or complaints regarding this
policy should be directed to Executive Director, Office
of Affirmative Action and Equal Opportunity Programs,
3600 Chestnut Street, Sansom Place East Suite 228,
Philadelphia, PA 19104-6106 or 215-898-6993 (Voice)
or 215-898-7803 (TDD). www.upenn.edu/affirm-action.
8:00 A.M. – 4:00 P.M.
FRIDAY, JANUARY 30, 2015
CME/CE-Certified Course
With Proceedings from
International Medical Meetings
UPDATE IN
HEMATOLOGIC
CANCERS
3600 Market Street
Suite 210
Philadelphia, PA 19104-2643
Permit No. 2563
Phila, PA 19176
PAID
PRESORTED
First Class Mail
U.S. Postage